Claire Bugos is a Senior News Reporter at Verywell Health. Based in New York, she specializes in public health and medicine, covering themes such as mental health, diet and nutrition, fitness, and consumer health. Her work has been featured in various outlets, including AOL, Inc., Yahoo News, and Smithsonian Magazine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Claire Bugos' coverage primarily focuses on healthcare and pharmaceutical topics, with an emphasis on citing data and press releases. She appears to value evidence-based reporting and may be more responsive to pitches that include scientific studies, clinical trial results, or expert commentary from reputable sources within the healthcare industry.
Given her focus on medical research, health issues, medications, and COVID-19 updates, Claire would likely be interested in receiving pitches related to breakthroughs in medical research or developments in the healthcare industry. Additionally, she might appreciate insights from professionals who can provide valuable perspectives on emerging health trends or innovative treatments.
It's important to note that Claire does not seem to have a specific geographic focus but rather covers global healthcare-related topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Claire Bugos for Understood Driving is full of distractions, from cellphones to other drivers on the road.
By: Claire Bugos
Esjwjoh jt gvmm pg ejtusbdujpot, gspn dfmmqipoft up puifs esjwfst po uif spbe. Cvu gps bevmut boe uffot efbmjoh xjui tznqupnt pg BEIE, mjlf jobuufoujpo boe jnqvmtjwjuz, uiptf ejtsvqujpot dbo nblf esjwjoh ftqfdjbmmz sjtlz.
By: Claire Bugos
Traffic jamming during rush hour in the city neighborhood at early evening. Thank you for reading!
Claire Bugos for Understood A new ADHD drug just got FDA approval. Here's what makes it different.
By: Claire Bugos
A conceptual illustration of providing medication to ADHD patients. Thank you for reading!
By: Claire Bugos
Understood reports that the FDA has approved Simtriyo, a new ADHD medication targeting dopamine, norepinephrine, and serotonin, promising fewer side effects.
Jack_the_sparow // Shutterstock A new ADHD drug just got FDA approval. Here's what makes it different.
Driving is full of distractions, from cellphones to other drivers on the road. But for adults and teens dealing with symptoms of ADHD, like inattention and impulsivity, those disruptions can make driving especially risky.
